Finance Watch: Forma Raises $100m In Quest To Become A Sickle Cell Leader

Forma Therapeutics Inc. has gone through a lot of change during the past year after its most lucrative partnership was downsized, but after adding $100m in series D venture capital to its balance sheet the company is ready to execute its new drug development strategy focused on rare hematologic diseases and cancers, including the pyruvate kinase-R (PKR) activator FT-4202 for sickle cell disease.

Cambridge, MA-based Forma hasn’t raised venture capital for seven years, because it brought in hundreds of millions of dollars from...